Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury

Delivery of a peptide (APP96-110), derived from amyloid precursor protein (APP), has been shown to elicit neuroprotective effects following cerebral stroke and traumatic brain injury. In this study, the effect of APP96-110 or a mutant version of this peptide (mAPP96-110) was assessed following moder...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stuart I Hodgetts, Sarah J Lovett, D Baron-Heeris, A Fogliani, Marian Sturm, C Van den Heuvel, Alan R Harvey
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2022
Materias:	amyloid precursor protein; cell transplantation; combination; contusion; functional recovery; mesenchymal stromal cells; neuroprotection; regeneration; spinal cord injury; tissue sparing Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b446304ce9f342ca8ba8d4910d9b57c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b446304ce9f342ca8ba8d4910d9b57c3
record_format	dspace
spelling	oai:doaj.org-article:b446304ce9f342ca8ba8d4910d9b57c32021-11-19T12:16:44ZEffects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury1673-537410.4103/1673-5374.327357https://doaj.org/article/b446304ce9f342ca8ba8d4910d9b57c32022-01-01T00:00:00Zhttp://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=6;spage=1376;epage=1386;aulast=Hodgettshttps://doaj.org/toc/1673-5374Delivery of a peptide (APP96-110), derived from amyloid precursor protein (APP), has been shown to elicit neuroprotective effects following cerebral stroke and traumatic brain injury. In this study, the effect of APP96-110 or a mutant version of this peptide (mAPP96-110) was assessed following moderate (200 kdyn, (2 N)) thoracic contusive spinal cord injury (SCI) in adult Nude rats. Animals received a single tail vein injection of APP96-110 or mAPP96-110 at 30 minutes post-SCI and were then assessed for functional improvements over the next 8 weeks. A cohort of animals also received transplants of either viable or non-viable human mesenchymal stromal cells (hMSCs) into the SC lesion site at one week post-injury to assess the effect of combining intravenous APP96-110 delivery with hMSC treatment. Rats were perfused 8 weeks post-SCI and longitudinal sections of spinal cord analyzed for a number of factors including hMSC viability, cyst size, axonal regrowth, glial reactivity and macrophage activation. Analysis of sensorimotor function revealed occasional significant differences between groups using Ladderwalk or Ratwalk tests, however there were no consistent improvements in functional outcome after any of the treatments. mAPP96-110 alone, and APP96-110 in combination with both viable and non-viable hMSCs significantly reduced cyst size compared to SCI alone. Combined treatments with donor hMSCs also significantly increased βIII tubulin+, glial fibrillary acidic protein (GFAP+) and laminin+ expression, and decreased ED1+ expression in tissues. This preliminary study demonstrates that intravenous delivery of APP96-110 peptide has selective, modest neuroprotective effects following SCI, which may be enhanced when combined with hMSC transplantation. However, the effects are less pronounced and less consistent compared to the protective morphological and cognitive impact that this same peptide has on neuronal survival and behaviour after stroke and traumatic brain injury. Thus while the efficacy of a particular therapeutic approach in one CNS injury model may provide justification for its use in other neurotrauma models, similar outcomes may not necessarily occur and more targeted approaches suited to location and severity are required. All animal experiments were approved by The University of Western Australia Animal Ethics Committee (RA3/100/1460) on April 12, 2016.Stuart I HodgettsSarah J LovettD Baron-HeerisA FoglianiMarian SturmC Van den HeuvelAlan R HarveyWolters Kluwer Medknow Publicationsarticleamyloid precursor protein; cell transplantation; combination; contusion; functional recovery; mesenchymal stromal cells; neuroprotection; regeneration; spinal cord injury; tissue sparingNeurology. Diseases of the nervous systemRC346-429ENNeural Regeneration Research, Vol 17, Iss 6, Pp 1376-1386 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	amyloid precursor protein; cell transplantation; combination; contusion; functional recovery; mesenchymal stromal cells; neuroprotection; regeneration; spinal cord injury; tissue sparing Neurology. Diseases of the nervous system RC346-429
spellingShingle	amyloid precursor protein; cell transplantation; combination; contusion; functional recovery; mesenchymal stromal cells; neuroprotection; regeneration; spinal cord injury; tissue sparing Neurology. Diseases of the nervous system RC346-429 Stuart I Hodgetts Sarah J Lovett D Baron-Heeris A Fogliani Marian Sturm C Van den Heuvel Alan R Harvey Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
description	Delivery of a peptide (APP96-110), derived from amyloid precursor protein (APP), has been shown to elicit neuroprotective effects following cerebral stroke and traumatic brain injury. In this study, the effect of APP96-110 or a mutant version of this peptide (mAPP96-110) was assessed following moderate (200 kdyn, (2 N)) thoracic contusive spinal cord injury (SCI) in adult Nude rats. Animals received a single tail vein injection of APP96-110 or mAPP96-110 at 30 minutes post-SCI and were then assessed for functional improvements over the next 8 weeks. A cohort of animals also received transplants of either viable or non-viable human mesenchymal stromal cells (hMSCs) into the SC lesion site at one week post-injury to assess the effect of combining intravenous APP96-110 delivery with hMSC treatment. Rats were perfused 8 weeks post-SCI and longitudinal sections of spinal cord analyzed for a number of factors including hMSC viability, cyst size, axonal regrowth, glial reactivity and macrophage activation. Analysis of sensorimotor function revealed occasional significant differences between groups using Ladderwalk or Ratwalk tests, however there were no consistent improvements in functional outcome after any of the treatments. mAPP96-110 alone, and APP96-110 in combination with both viable and non-viable hMSCs significantly reduced cyst size compared to SCI alone. Combined treatments with donor hMSCs also significantly increased βIII tubulin+, glial fibrillary acidic protein (GFAP+) and laminin+ expression, and decreased ED1+ expression in tissues. This preliminary study demonstrates that intravenous delivery of APP96-110 peptide has selective, modest neuroprotective effects following SCI, which may be enhanced when combined with hMSC transplantation. However, the effects are less pronounced and less consistent compared to the protective morphological and cognitive impact that this same peptide has on neuronal survival and behaviour after stroke and traumatic brain injury. Thus while the efficacy of a particular therapeutic approach in one CNS injury model may provide justification for its use in other neurotrauma models, similar outcomes may not necessarily occur and more targeted approaches suited to location and severity are required. All animal experiments were approved by The University of Western Australia Animal Ethics Committee (RA3/100/1460) on April 12, 2016.
format	article
author	Stuart I Hodgetts Sarah J Lovett D Baron-Heeris A Fogliani Marian Sturm C Van den Heuvel Alan R Harvey
author_facet	Stuart I Hodgetts Sarah J Lovett D Baron-Heeris A Fogliani Marian Sturm C Van den Heuvel Alan R Harvey
author_sort	Stuart I Hodgetts
title	Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
title_short	Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
title_full	Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
title_fullStr	Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
title_full_unstemmed	Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
title_sort	effects of amyloid precursor protein peptide app96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury
publisher	Wolters Kluwer Medknow Publications
publishDate	2022
url	https://doaj.org/article/b446304ce9f342ca8ba8d4910d9b57c3
work_keys_str_mv	AT stuartihodgetts effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT sarahjlovett effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT dbaronheeris effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT afogliani effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT mariansturm effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT cvandenheuvel effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury AT alanrharvey effectsofamyloidprecursorproteinpeptideapp96110aloneorwithhumanmesenchymalstromalcellsonrecoveryafterspinalcordinjury
_version_	1718420091317518336

Effects of amyloid precursor protein peptide APP96-110, alone or with human mesenchymal stromal cells, on recovery after spinal cord injury

Ejemplares similares